A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects with Type 2 Diabetes Mellitus

Exclusion Criteria

• - Has been treated with exenatide (BYETTA®) or any DPP-4 inhibitor prior to
• screening
• - Received any study medication or participated in any type of clinical trial
• within 30 days prior to screening
• - Has donated blood within 60 days of screening visit or is planning to donate blood during the study
• - Treated with any of the following medications:
• • Sulfonylurea or Thiazolidinedione within 3 months of screening;
• • Alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide
• (SYMLIN®)within 30 days of screening;
• • Insulin within 2 weeks prior to screening or insulin for longer than 1
• week within 6 months of screening;
• • Drugs that directly affect gastrointestinal motility, including but not
• limited to, anticholinergics, macrolide antibiotics,
• dopamine antagonists, opioids, and Reglan®(metoclopramide);
• • Systemic corticosteroids by oral, intravenous, or intramuscular route;
• or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known
• to have a high rate of systemic absorption;